Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: an Analysis of the FDA Adverse Event Reporting System database (FAERS).
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2244
Abstract: The cardiovascular and cerebrovascular safety of ranibizumab, bevacizumab, and aflibercept for ocular diseases is unclear. This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for… read more here.
Keywords: ranibizumab bevacizumab; cardiovascular cerebrovascular; bevacizumab aflibercept; bevacizumab ... See more keywords